Trial Profile
A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-Cell Non-Hodgkin Lymphoma (NHL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Umbralisib (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 26 Jan 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2027.
- 26 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2027.
- 15 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.